Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

Shares of NASDAQ TRVN opened at $1.81 on Friday. The company has a fifty day moving average price of $1.71 and a 200 day moving average price of $2.67. Trevena has a 1-year low of $1.13 and a 1-year high of $17.50. The firm has a market cap of $1.56 million, a PE ratio of -0.04 and a beta of 1.08.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.